Diabetes mellitus in stable chronic heart failure and the combination with humoral activation, their association, and prediction of 2‐year adverse outcomes. Data from the FAR NHL registry

Karel Labr,Jindrich Spinar,Jiri Parenica,Lenka Spinarova,Jan Krejci,Filip Malek,Petr Ostadal,Ondrej Ludka,Jiri Jarkovsky,Klara Benesova,Ruzena Labrova,Monika Spinarova
DOI: https://doi.org/10.1111/1753-0407.13605
IF: 4.53
2024-09-14
Journal of Diabetes
Abstract:Highlights Diabetic patients more often has comorbidities such as ischemic heart disease, hypertension, dyslipidemia, or renal impairment, higher uric acid, lower hemoglobin, and lower eGFR. Based on a large prospective multicenter registry, we found that the combination of diabetes and NT‐proBNP levels may help stratify the prognosis of patients with chronic heart failure when the NT‐proBNP level is low. High NT‐proBNP is in itself a strong predictor of events (all‐cause death, left ventricle assist device implantation, and orthotopic heart transplantation), that the addition of diabetes mellitus will no longer improve the stratification of patient prognosis in this group. Background/Aim The study aims to describe the role of diabetes in patients with heart failure. Methods In all, 1052 chronic heart failure patients were included in the FARmacology and NeuroHumoral Activation (FAR NHL) multicenter prospective registry. They had ejection fraction below 50% and were on stable medication for at least 1 month. Results More than one‐third (38.9%) of the patients had diabetes mellitus (DM). Diabetic patients (N = 409) were older (median 67 vs. 64, p
endocrinology & metabolism
What problem does this paper attempt to address?